Trial Profile
A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VIKING-3
- Sponsors ViiV Healthcare
- 12 May 2022 A systematic literature review was conducted to identify trials with designs and populations comparable to BRIGHTE, results published in the Clinical Therapeutics
- 06 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2013 Results for pre-specified univariate subgroups presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.